US EditionBlood test for early signs of pancreatic cancer trialled by UK doctors
- UK doctors are conducting trials of a new blood test called Avantect to identify early-stage pancreatic cancer in individuals who have been newly diagnosed with type 2 diabetes.
- The trial responds to the challenge that pancreatic cancer is often diagnosed late due to vague symptoms and lack of targeted early detection tests.
- The Avantect test, which detects pancreatic cancer markers in blood samples, is currently being assessed in a study involving 800 participants at the Southampton clinical trials facility supported by Cancer Research UK.
- Preliminary findings show the Avantect test correctly detects early cancer in 68 percent of cases and correctly identifies 97 percent of individuals who do not have the disease.
- If successful, the test could improve early pancreatic cancer diagnosis, which is critical as over 80 percent of cases are currently detected too late for effective treatment.
Insights by Ground AI
Does this summary seem wrong?
21 Articles
21 Articles
All
Left
3
Center
6
Right
2
Pancreatic cancer is one of the most lethal diseases and is almost too late to be treated more effectively. A new innovative genetic test, found at the test stage in the British Sea, promises to change this reality. Designed...
·Romania
Read Full Article
Coverage Details
Total News Sources21
Leaning Left3Leaning Right2Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 27%
C 55%
R 18%
Factuality
To view factuality data please Upgrade to Premium
